<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02802449</url>
  </required_header>
  <id_info>
    <org_study_id>11-08-2333</org_study_id>
    <secondary_id>7U54MD008149</secondary_id>
    <nct_id>NCT02802449</nct_id>
  </id_info>
  <brief_title>To Study the Nutri-Genomic Response of Vit-D Supplementation in African-Americans</brief_title>
  <official_title>An Eight Week Double Blinded Randomized, Placebo-controlled Trial to Assess the Effect of Two Doses of 100,000 IU Vitamin D3 by Mouth on Select Genetic Responses in Overweight, Hypertensive African-Americans With Hypovitaminosis D</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charles Drew University of Medicine and Science</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Morehouse School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Minority Health and Health Disparities (NIMHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Charles Drew University of Medicine and Science</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Three hundred thirty (330) overweight, pre-hypertensive/controlled hypertensive,&#xD;
      African-American participants will be enrolled in a 8 week study to assess the effect of two&#xD;
      administrations of Vitamin D3 on Vitamin D serum responsiveness as a function of clinical,&#xD;
      biologic and genetic factors. The investigators anticipate that at least 300 participants&#xD;
      will complete this study.&#xD;
&#xD;
      Written, signed and dated informed consent to participate in the study will be given by the&#xD;
      participant or a legally acceptable representative, in accordance with the International&#xD;
      Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guideline E6 and applicable&#xD;
      regulations, before completing any study-related activities/procedures. The original signed&#xD;
      and dated consent will be kept in the subject's research file and a copy given to the&#xD;
      subject. A copy will also be placed in their medical record.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DETAILED DESCRIPTION OF STUDY PROCEDURES. Three hundred thirty (330) overweight,&#xD;
      pre-hypertensive/controlled hypertensive, African-American participants will be enrolled in a&#xD;
      8 week study to assess the effect of two administrations of Vitamin D3 on Vitamin D serum&#xD;
      responsiveness as a function of clinical, biologic and genetic factors. The investigators&#xD;
      anticipate that at least 300 participants will complete this study.&#xD;
&#xD;
      Written, signed and dated informed consent to participate in the study will be given by the&#xD;
      participant or a legally acceptable representative, in accordance with the International&#xD;
      Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guideline E6 and applicable&#xD;
      regulations, before completing any study-related activities/procedures. The original signed&#xD;
      and dated consent will be kept in the subject's research file and a copy given to the&#xD;
      subject. A copy will also be placed in their medical record.&#xD;
&#xD;
      BLOOD PRESSURE CONTROL. Controlled high blood pressure is entry criteria, but not an outcome.&#xD;
      However, the investigators want to exclude potential participants who are likely to have poor&#xD;
      BP control during the study. Therefore, although patients with pre-hypertension or&#xD;
      hypertension are eligible to be entered into the study, the protocol only allows enrollment&#xD;
      of participants with well-controlled hypertension as defined by SBP≥ 120 mmHg or DBP ≥ 80&#xD;
      mmHg if not on treatment, and SBP &lt;160 mmHg or DBP &lt; 100 mmHg regardless of whether on&#xD;
      treatment or not. BP care will be managed by the participants' primary or other provider. All&#xD;
      participants being actively treated for hypertension with pharmacotherapy will receive&#xD;
      direction to adhere to their medication and to follow-up with their Primary Care Physician.&#xD;
      Patients with poorly controlled diabetes as defined by hemoglobin A1c &gt; 8.5% or advanced&#xD;
      kidney disease as defined by eGFR &lt; 45 ml/min are excluded. After the study is concluded, all&#xD;
      participants will be encouraged and supported to address issues of diet and exercise that may&#xD;
      reduce their risk for hypertension. If BP medications need to be adjusted, participants will&#xD;
      be referred back to their Primary Care Physician.&#xD;
&#xD;
      VISIT 1 - SCREENING. The screening period will allow for the determination of appropriateness&#xD;
      of each subject's inclusion in the study. Written informed consent from the subject or their&#xD;
      legally authorized representative would have been obtained prior to any study-related&#xD;
      procedures being performed. In addition to signing the general informed consent, subjects who&#xD;
      agree to participate the sub-study with fat biopsy will sign a second informed consent.&#xD;
&#xD;
      The subject will be assigned a screening number and will be contacted regarding eligibility&#xD;
      once all screening procedures have been performed and laboratory results received.&#xD;
&#xD;
      The following evaluations and assessments will be performed during Screening:&#xD;
&#xD;
      inclusion/exclusion criteria, medical history (including demographics and concomitant&#xD;
      medications, including prescription, herbal/vitamins, and all over-the-counter medications),&#xD;
      vital signs (sitting BP, heart rate), and a mini physical examination (which will include&#xD;
      height (cm), weight (kg), and waist circumference (cm) from which body mass index (BMI) will&#xD;
      be calculated and a clinical heart/lung examination. Blood will be drawn (15 cc) for full&#xD;
      biochemistry panel with glucose (mg/dl), complete blood count, HbA1c (%), calcium (mg/dl),&#xD;
      phosphorus (mg/dl), albumin (mg/dl), pregnancy test and 25(OH)D (ng/ml) levels. After&#xD;
      screening information is reviewed and deemed to be appropriate for inclusion in the study,&#xD;
      eligible subjects will be given an appointment and preparatory instructions for Visit 2&#xD;
      (Baseline/Randomization/Dose#1). Instructions include cessation of smoking (if they smoke),&#xD;
      eating, or drinking caffeine for at least 8 hours prior to the Baseline Visit. If&#xD;
      participants are taking prescribed medications, they will be asked to bring them and advised&#xD;
      to take them as prescribed.&#xD;
&#xD;
      VISIT 2 - BASELINE/ RANDOMIZATION/ STUDY DRUG DOSE#1 ADMINISTRATION. If subject meets all of&#xD;
      the inclusion/exclusion criteria, they will be randomized. The participant will be asked&#xD;
      about any adverse events and changes in medications, including prescription, herbal/vitamin,&#xD;
      and over-the-counter medications. Vital signs (sitting BP, heart rate) will be obtained and a&#xD;
      nutritional survey administered. Blood will be drawn (45 cc) for serum calcium (mg/dl),&#xD;
      phosphorus (mg/dl), albumin (mg/dl), iPTH (pg/ml) and 1-84 PTH/7-84 PTH ratio, pregnancy&#xD;
      test, 25(OH)D (ng/ml) levels; and samples stored for bio-markers (e.g.&#xD;
      pro-inflammatory/pro-thrombotic/fibrotic, insulin sensitivity, and vitamin D receptor&#xD;
      polymorphisms). Spot urine sample (30cc) will be collected for calcium/creatinine and&#xD;
      albumin/creatinine ratios as well as sodium and isoprostanes. The fat biopsy will be&#xD;
      performed on those that agree to be part of the subgroup. Participants undergoing the fat&#xD;
      biopsy will be given post biopsy instructions including a return appointment in 7-10 days.&#xD;
&#xD;
      Visit will last about 30-60 minutes for most participants. At the end of the visit,&#xD;
      participant will be randomized and given either two 50,000 IU tablets of oral Vitamin D3&#xD;
      [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] or two tablets of&#xD;
      Placebo (microcrystalline cellulose) to take under direct observation. All the participants&#xD;
      will be given an appointment and preparatory instructions for Study Visit 3. They will also&#xD;
      be asked to avoid any other vitamin D supplements during study period.&#xD;
&#xD;
      VISIT 3 - STUDY DRUG DOSE#2 ADMINISTRATION (2 weeks after baseline). Visit will last about 15&#xD;
      minutes for most participants. Participant will be asked about any adverse events and changes&#xD;
      in medications, including prescription, herbal, and over-the-counter medications. Vital signs&#xD;
      will be obtained. Participant will be given their second dose of either two 50,000 IU tablets&#xD;
      of oral Vitamin D3 or two tablets of Placebo to take under direct observation. All the&#xD;
      participants will be given an appointment and preparatory instructions for Study Visit 4&#xD;
      (Week 6).&#xD;
&#xD;
      VISIT 4 (Week 6). During this visit participant will be asked about any adverse events&#xD;
      including possible symptoms of vitamin D overdose and changes in medications, including&#xD;
      prescription, herbal, and over-the-counter medications. In addition, the following&#xD;
      evaluations and assessments will also be performed: vital signs (sitting BP, heart rate).&#xD;
      Blood will be drawn (3 tablespoon or 45 cc) for full biochemistry panel, with glucose&#xD;
      (mg/dl), HbA1c (%), complete blood count, calcium (mg/dl), phosphorus (mg/dl), albumin&#xD;
      (mg/dl), iPTH (pg/ml) and 1-84 PTH/7-84 PTH ratio, and 25(OH)D (ng/ml) levels; and stored&#xD;
      samples for bio markers (e.g. pro-inflammatory/pro- thrombotic/fibrotic, insulin sensitivity,&#xD;
      and vitamin D receptor polymorphisms). Spot urine sample will be collected for&#xD;
      calcium/creatinine and albumin/creatinine ratios as well as sodium and isoprostanes. Urine&#xD;
      pregnancy test will also be done. Participants undergoing the fat biopsy will be given post&#xD;
      biopsy instructions and will have an additional 7-10 days of follow-up.&#xD;
&#xD;
      VISIT 5 - END OF STUDY (Week 8). At the End of Study visit (EOS), participant will be asked&#xD;
      about any adverse events including possible symptoms of vitamin D overdose. In addition, the&#xD;
      following evaluations and assessments will also be performed: vital signs (sitting BP and&#xD;
      heart rate). The results of the labs from the previous visit will be discussed and if there&#xD;
      are any abnormal lab values, participant will be referred to primary care physician for&#xD;
      further management.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2013</start_date>
  <completion_date type="Actual">July 2018</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma PTH Level</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Building upon our hypothesis above, this aim exploits the fact that the nuclear Vit-D Receptor (VDR) regulates parathyroid hormone (PTH) gene transcription. Therefore the plasma PTH level serves as a sensitive biomarker of the Vit-D nutri-genomic response. This aim will define the multivariate determinants (covariates such as age, BMI, baseline Vit-D level and dietary calcium) of the Vit-D-PTH level relationship (the primary outcome variable) in African-Americans. It is anticipated that the Vit-D supplementation trial will document a wide variance of Vit-D-PTH level relationships that will identify patients at the upper and lower quartiles of the distribution that are either 'nutrient-responsive' or 'nutrient-resistant'. These studies should help identify the 'clinical' characteristics of the sub-set of African-Americans that exhibit the poorest response to Vit-D supplementation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vitamin D3 Level</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxidative Stress Markers: Cysteine</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative Stress Markers: Homocysteine</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative Stress Markers: GSH</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative Stress Markers: Isoprostane</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">330</enrollment>
  <condition>Hypovitaminosis D</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The participant will be randomized to receive two tablets of Placebo (microcrystalline cellulose) to take under direct observation at the baseline and week 2 visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25 hydroxy-Vitamin D3 or [25 (OH) D3]</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The participant will be randomized to receive two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] to take under direct observation at the baseline and week 2 visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>25 Hydroxy- Vitamin D3 [25 (OH) D3]</intervention_name>
    <description>Two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.</description>
    <arm_group_label>25 hydroxy-Vitamin D3 or [25 (OH) D3]</arm_group_label>
    <other_name>Vitamin D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females, 18-70 years of age and self-identified as African-American or Black&#xD;
&#xD;
          -  Pre-hypertension or hypertension (well controlled - see below)&#xD;
&#xD;
          -  If a potential study patient is not on treatment their SBP must be &gt; 120 mmHg, or DBP&#xD;
             &gt; 80 mmHg&#xD;
&#xD;
          -  Whether on treatment or not SBP must be &lt;160 mmHg and DBP must be &lt; 100 mmHg (BP is&#xD;
             not an outcome. Controlled BP is for participant safety)&#xD;
&#xD;
          -  Screening Vitamin D (D2 and D3 level) &gt;5 and &lt; 25 ng/ml (recommended normal level is &gt;&#xD;
             30 ng/ml)&#xD;
&#xD;
          -  Body mass index (BMI) &gt; 25 kg/m2 and &lt; 45 kg/m2&#xD;
&#xD;
          -  Any female of non-childbearing potential, including any female who:&#xD;
&#xD;
               -  has had a hysterectomy,&#xD;
&#xD;
               -  has had a bilateral oophorectomy,&#xD;
&#xD;
               -  has had a bilateral tubal ligation or&#xD;
&#xD;
               -  is postmenopausal (demonstration of total cessation of menses for ≥ 1 year prior&#xD;
                  to the date of the screening visit)&#xD;
&#xD;
          -  Any female of child-bearing potential must agree to use at least one form of&#xD;
             contraception (may be a barrier method), during the full duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent Disease:&#xD;
&#xD;
               -  Poorly controlled high blood pressure (SBP ≥160 mmHg or DBP ≥ 100 mmHg)&#xD;
&#xD;
               -  Poorly controlled diabetes (HbA1c &gt;8.5%)&#xD;
&#xD;
               -  Screening Vitamin D (D2 and D3 level) &lt; 5 or &gt; 25 ng/ml (recommended normal level&#xD;
                  is &gt; 30 ng/ml)&#xD;
&#xD;
               -  Estimated glomerular filtration rate (eGFR) &lt; 45 ml/min&#xD;
&#xD;
               -  Evidence of disease that could result in hypercalcemia&#xD;
&#xD;
               -  History of kidney stones (less than one year prior to screening)&#xD;
&#xD;
               -  History of drug, alcohol, or illicit substance abuse (within the past 6 months)&#xD;
&#xD;
               -  History of another chronic disease which the investigator feels should preclude&#xD;
                  the subject from entering the study (e.g. cancer, immunologic disorder)&#xD;
&#xD;
               -  Liver function tests (LFTs) greater than twice the upper limit of normal&#xD;
&#xD;
               -  Subjects requiring chronic use of nonsteroidal anti-inflammatory drugs or aspirin&#xD;
                  &gt;325 mg/day&#xD;
&#xD;
               -  Subjects requiring treatment with other vitamin D preparations containing more&#xD;
                  than 400 IU of vitamin D&#xD;
&#xD;
               -  Subjects requiring chronic use of immunosuppressive therapy or corticosteroids&#xD;
&#xD;
               -  Recent (&lt;6 months) myocardial infarction, stroke, or hospitalization for&#xD;
                  congestive heart failure&#xD;
&#xD;
               -  Subjects with clinically apparent hypothyroidism or thyrotoxicosis&#xD;
&#xD;
               -  Allergy/intolerance: known allergy to oral vitamin D or microcrystalline&#xD;
                  cellulose&#xD;
&#xD;
               -  Any female of child-bearing potential who declines to use some method of birth&#xD;
                  control during the study period&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Concurrent participation in other clinical trials or taking experimental medications&#xD;
             or within 30 days of completing another trial or study.&#xD;
&#xD;
          -  Patients who are unable to give informed consent&#xD;
&#xD;
          -  Patients who, in the opinion of the Investigator, have a condition which would&#xD;
             interfere with their evaluation (e.g. severe mental health disorder)&#xD;
&#xD;
          -  Patients who, in the opinion of the Investigator, may experience an unacceptable&#xD;
             health risk by participating in this study&#xD;
&#xD;
          -  Patients who are pregnant or lactating&#xD;
&#xD;
          -  Not African- American or Black by self-identification&#xD;
&#xD;
          -  Body mass index (BMI) &gt; 45 kg/m2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Martins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charles Drew University of Medicine and Science</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charles Drew University</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90059</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>April 8, 2016</study_first_submitted>
  <study_first_submitted_qc>June 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2016</study_first_posted>
  <results_first_submitted>March 22, 2018</results_first_submitted>
  <results_first_submitted_qc>April 26, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 24, 2018</results_first_posted>
  <last_update_submitted>January 30, 2019</last_update_submitted>
  <last_update_submitted_qc>January 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charles Drew University of Medicine and Science</investigator_affiliation>
    <investigator_full_name>David Martins</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>Hypovitaminosis D</keyword>
  <keyword>HTN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rickets</mesh_term>
    <mesh_term>Avitaminosis</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcifediol</mesh_term>
    <mesh_term>Hydroxycholecalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>The participant will be randomized then given two tablets of Placebo (microcrystalline cellulose) to take under direct observation at the baseline and week 2 visit.&#xD;
Placebo</description>
        </group>
        <group group_id="P2">
          <title>25 Hydroxy-Vitamin D3 or [25 (OH) D3]</title>
          <description>The participant will be randomized then given two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] to take under direct observation at the baseline and week 2 visit.&#xD;
25 Hydroxy- Vitamin D3 [25 (OH) D3]: Two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="219"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="202"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>The participant will be randomized then given two tablets of Placebo (microcrystalline cellulose) to take under direct observation at the baseline and week 2 visit.&#xD;
Placebo</description>
        </group>
        <group group_id="B2">
          <title>25 Hydroxy-Vitamin D3 or [25 (OH) D3]</title>
          <description>The participant will be randomized then given two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] to take under direct observation at the baseline and week 2 visit.&#xD;
25 Hydroxy- Vitamin D3 [25 (OH) D3]: Two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="111"/>
            <count group_id="B2" value="219"/>
            <count group_id="B3" value="330"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.3" spread="9.7"/>
                    <measurement group_id="B2" value="51.3" spread="9.7"/>
                    <measurement group_id="B3" value="52.0" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="219"/>
                    <measurement group_id="B3" value="330"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="219"/>
                    <measurement group_id="B3" value="330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma PTH Level</title>
        <description>Building upon our hypothesis above, this aim exploits the fact that the nuclear Vit-D Receptor (VDR) regulates parathyroid hormone (PTH) gene transcription. Therefore the plasma PTH level serves as a sensitive biomarker of the Vit-D nutri-genomic response. This aim will define the multivariate determinants (covariates such as age, BMI, baseline Vit-D level and dietary calcium) of the Vit-D-PTH level relationship (the primary outcome variable) in African-Americans. It is anticipated that the Vit-D supplementation trial will document a wide variance of Vit-D-PTH level relationships that will identify patients at the upper and lower quartiles of the distribution that are either 'nutrient-responsive' or 'nutrient-resistant'. These studies should help identify the 'clinical' characteristics of the sub-set of African-Americans that exhibit the poorest response to Vit-D supplementation.</description>
        <time_frame>Baseline and Week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>The participant will be randomized then given two tablets of Placebo (microcrystalline cellulose) to take under direct observation at the baseline and week 2 visit.&#xD;
Placebo</description>
          </group>
          <group group_id="O2">
            <title>25 Hydroxy-Vitamin D3 or [25 (OH) D3]</title>
            <description>The participant will be randomized then given two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] to take under direct observation at the baseline and week 2 visit.&#xD;
25 Hydroxy- Vitamin D3 [25 (OH) D3]: Two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma PTH Level</title>
          <description>Building upon our hypothesis above, this aim exploits the fact that the nuclear Vit-D Receptor (VDR) regulates parathyroid hormone (PTH) gene transcription. Therefore the plasma PTH level serves as a sensitive biomarker of the Vit-D nutri-genomic response. This aim will define the multivariate determinants (covariates such as age, BMI, baseline Vit-D level and dietary calcium) of the Vit-D-PTH level relationship (the primary outcome variable) in African-Americans. It is anticipated that the Vit-D supplementation trial will document a wide variance of Vit-D-PTH level relationships that will identify patients at the upper and lower quartiles of the distribution that are either 'nutrient-responsive' or 'nutrient-resistant'. These studies should help identify the 'clinical' characteristics of the sub-set of African-Americans that exhibit the poorest response to Vit-D supplementation.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.29" spread="23.82"/>
                    <measurement group_id="O2" value="60.73" spread="26.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.88" spread="22.23"/>
                    <measurement group_id="O2" value="54.05" spread="26.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vitamin D3 Level</title>
        <time_frame>Baseline and Week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>The participant will be randomized then given two tablets of Placebo (microcrystalline cellulose) to take under direct observation at the baseline and week 2 visit.&#xD;
Placebo</description>
          </group>
          <group group_id="O2">
            <title>25 Hydroxy-Vitamin D3 or [25 (OH) D3]</title>
            <description>The participant will be randomized then given two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] to take under direct observation at the baseline and week 2 visit.&#xD;
25 Hydroxy- Vitamin D3 [25 (OH) D3]: Two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.</description>
          </group>
        </group_list>
        <measure>
          <title>Vitamin D3 Level</title>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.02" spread="4.51"/>
                    <measurement group_id="O2" value="16.55" spread="4.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.64" spread="4.90"/>
                    <measurement group_id="O2" value="32.73" spread="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxidative Stress Markers: Cysteine</title>
        <time_frame>Baseline and Week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>The participant will be randomized then given two tablets of Placebo (microcrystalline cellulose) to take under direct observation at the baseline and week 2 visit.&#xD;
Placebo</description>
          </group>
          <group group_id="O2">
            <title>25 Hydroxy-Vitamin D3 or [25 (OH) D3]</title>
            <description>The participant will be randomized then given two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] to take under direct observation at the baseline and week 2 visit.&#xD;
25 Hydroxy- Vitamin D3 [25 (OH) D3]: Two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.</description>
          </group>
        </group_list>
        <measure>
          <title>Oxidative Stress Markers: Cysteine</title>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cysteine (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253.5" spread="41.5"/>
                    <measurement group_id="O2" value="252.4" spread="35.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cysteine (Week 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="249.0" spread="38.7"/>
                    <measurement group_id="O2" value="241.2" spread="32.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxidative Stress Markers: Homocysteine</title>
        <time_frame>Baseline and Week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>The participant will be randomized then given two tablets of Placebo (microcrystalline cellulose) to take under direct observation at the baseline and week 2 visit.&#xD;
Placebo</description>
          </group>
          <group group_id="O2">
            <title>25 Hydroxy-Vitamin D3 or [25 (OH) D3]</title>
            <description>The participant will be randomized then given two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] to take under direct observation at the baseline and week 2 visit.&#xD;
25 Hydroxy- Vitamin D3 [25 (OH) D3]: Two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.</description>
          </group>
        </group_list>
        <measure>
          <title>Oxidative Stress Markers: Homocysteine</title>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Homocysteine (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="3.3"/>
                    <measurement group_id="O2" value="11.9" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Homocysteine (Week 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" spread="3.0"/>
                    <measurement group_id="O2" value="11.8" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxidative Stress Markers: GSH</title>
        <time_frame>Baseline and Week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>The participant will be randomized then given two tablets of Placebo (microcrystalline cellulose) to take under direct observation at the baseline and week 2 visit.&#xD;
Placebo</description>
          </group>
          <group group_id="O2">
            <title>25 Hydroxy-Vitamin D3 or [25 (OH) D3]</title>
            <description>The participant will be randomized then given two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] to take under direct observation at the baseline and week 2 visit.&#xD;
25 Hydroxy- Vitamin D3 [25 (OH) D3]: Two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.</description>
          </group>
        </group_list>
        <measure>
          <title>Oxidative Stress Markers: GSH</title>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSH (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="1.2"/>
                    <measurement group_id="O2" value="4.1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSH (Week 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="0.9"/>
                    <measurement group_id="O2" value="3.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxidative Stress Markers: Isoprostane</title>
        <time_frame>Baseline and Week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>The participant will be randomized then given two tablets of Placebo (microcrystalline cellulose) to take under direct observation at the baseline and week 2 visit.&#xD;
Placebo</description>
          </group>
          <group group_id="O2">
            <title>25 Hydroxy-Vitamin D3 or [25 (OH) D3]</title>
            <description>The participant will be randomized then given two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] to take under direct observation at the baseline and week 2 visit.&#xD;
25 Hydroxy- Vitamin D3 [25 (OH) D3]: Two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.</description>
          </group>
        </group_list>
        <measure>
          <title>Oxidative Stress Markers: Isoprostane</title>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Isoprostane (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8298.6" spread="8504.8"/>
                    <measurement group_id="O2" value="11914.9" spread="17904.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Isoprostane (Week 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="687.1" spread="54460.2"/>
                    <measurement group_id="O2" value="9979.7" spread="8630.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected throughout duration of study = 12 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>The participant will be randomized then given two tablets of Placebo (microcrystalline cellulose) to take under direct observation at the baseline and week 2 visit.&#xD;
Placebo</description>
        </group>
        <group group_id="E2">
          <title>25 Hydroxy-Vitamin D3 or [25 (OH) D3]</title>
          <description>The participant will be randomized then given two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] to take under direct observation at the baseline and week 2 visit.&#xD;
25 Hydroxy- Vitamin D3 [25 (OH) D3]: Two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Blood Pressure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fractured Right Arm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Neck Strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Right Leg Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Back Pain Exacerbation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Chest Sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Left Shoulder Muscle Strain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Neck Muscle Cramp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Lab Value</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Injury - Right Lower Extremity (Pre-Existing)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Skin Lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Rash on Bilateral Lower Extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David Martins</name_or_title>
      <organization>Charles Drew University of Medicine and Science</organization>
      <phone>323-568-3353</phone>
      <email>davidmartins@cdrewu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

